Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

NCT ID: NCT03994744

Last Updated: 2019-08-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-20
• Study Completion Date: 2022-07-01

Brief Summary

In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin.

Primary outcome:

Objective response rate (ORR), Safety of the combination therapy

Secondary outcome:

Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),

Detailed Description

Exploratory Endpoints:

The association between the efficacy of the combination treatment and changes in CTC counts after administration of the treatment.

Evaluating the correlation between programmed death ligand 1 (PD-L1) expression derived from circulating tumor cells (CTC) and tumor tissue cells, and the predictive role of CTC PD-L1 expression in ED-SCLC.

The compositional changes in the gut microbiota after administration of the treatment and its association with the efficacy of the combination treatment.

Conditions

Small-cell Lung Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer Recurrent; Small Cell Lung Cancer Extensive Stage

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sintilimab and Metformin

Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).

The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up.

Group Type: EXPERIMENTAL

PD-1 inhibitor

Intervention Type: DRUG

Intravenous administration of Sintilimab (1200mg/3weeks)

Metformin

Intervention Type: DRUG

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.

Interventions

PD-1 inhibitor

Intravenous administration of Sintilimab (1200mg/3weeks)

Intervention Type: DRUG

Metformin

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.

Intervention Type: DRUG

Other Intervention Names

Sintilimab; IBI380

Eligibility Criteria

Inclusion Criteria

1. Male or female patient, age≥18 and≤65;

2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;

3. The life expectancy of greater than 12 weeks;

4. Participants must have histologically or cytologically confirmed metastatic or extended disease of SCLC (ED-SCLC).

5. According to RECIST1.1, participants must have been confirmed Disease progression (within 6 months, confirmed by imaging test)after platinum-based doublet chemotherapy OR after (PFS>6 months, ) platinum-based doublet chemotherapy and refused to continue chemotherapy, OR after second-line or more lines of systemic chemotherapy limited disease SCLC (LD-SCLC) patients with disease progression after Synchronous chemoradiotherapy, must receive firstline systematic platinum-based doublet chemotherapy and refused to receive chemotherapy again.

6. Evaluable or measurable lesion is required, defined as at least one lesion (not brain metastasis) that can be accurately measured based on RECIST 1.1;

7. Participant need to provided tumor tissue (from an archival tumor sample obtained within 1 year or from a new biopsy sample) for PD-L1 immunohistochemical (IHC) assay, and PD-L1expression in more than 1% cells is required;

8. Participant is able to the ability to swallow oral medications

9. Participants have to meet the following criteria to ensure function of vital organs:

Absolute neutrophil count (ANC) ≥1.5×109/L or White blood cell count >3.5×109/L;Platelets >80×109/L; Hemoglobin (HGB)≥90 g/L;Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤2.5 ×ULN; ALB≥2.8g/dL;Serum creatinine ≤ 1.5 x institutional ULN OR creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation

10. Participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) through the treatment, and for at least 180 days after the last dose of study treatment; Participants must have the ability to understand and be willing to sign a written informed consent document.

Exclusion Criteria

1. Participants who were diagnosed as mixed pathological type of small cell lung cancer

2. Participants who had long-term use of metformin (>2 weeks) 6 months prior to study entry, or diagnosed with type-2 diabetes,

3. Participants received treatment with anti-PD1, -PDL1, -CTLA4, -CD137 inhibitors before, or any therapy specifically targeting T-cell co-stimulation or checkpoint pathways.

4. Participants received cellular immunotherapy before

5. Participants with Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection; Known history of Human Immunodeficiency Virus (HIV) infection Acute or chronic active hepatitis B (HBV DNA >1*10^3 copies/ml or >200 IU/mL) or, acute or chronic active hepatitis C (with a positive Hepatitis C antibody test result) Active tuberculosis Congestive heart failure (Class III-IV, according to New York Heart Association classification), or and clinically significant Cardiac arrhythmia if poorly controlled; Uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) Any arterial thrombosis, embolism, ischemia, myocardial infarction, unstable angina, or cerebrovascular accident within 6 months prior to enrollment,

6. Participants with symptomatic Central nervous metastasis or meningeal carcinomatosis are excluded; Participants with asymptomatic brain metastases or with brain metastases that have been treated and stable in a subsequent scan are allowed to include if there is measurable lesion outside the Central nervous system and no history of intracranial hemorrhage, and not midbrain, pons, cerebellum, medulla or spinal cord metastasis, and do not need glucocorticoid therapy.

7. Participants receiving glucocorticoid (>30 mg prednisone equivalent a day) or any Immunosuppressive drug within 14 days prior to study recruitment; Participants receiving inhaled or Topical corticosteroids, adrenal corticosteroid replacement therapy (>10 mg prednisone equivalent a day) are allowed if they have no active autoimmune disease

8. Participants with a known additional malignancy (Except for Non-melanoma skin cancer and the following in situ carcinoma: in situ bladder carcinoma, in situ gastric carcinoma, in situ colonic carcinoma, in situ endometrial carcinoma, in situ cervical carcinoma /dysplasia, in situ melanoma carcinoma and in situ breast Carcinoma) unless they Maintained Complete Remission for at least 5 years and do not need corresponding treatment during the study

9. Participants who have not recovered (i.e., ≤ Grade 1 according to NCI CTCAE V4or at baseline) from adverse effects due to a previously administered agent.

10. Participants who have uncontrollable effusion, such as pleural and ascites that cannot be controlled by drainage or other treatment

11. Patients who have active autoimmune diseases; excluding patients whose active autoimmune disease is caused by Vitiligo or asthma that is completely relieved in childhood and Patients with hypothyroidism requiring only hormone replacement therapy

12. Patients with known Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation

13. Patients who are pregnant or breastfeeding,

14. Patients who are allergic to monoclonal antibody drugs

15. Patients who have contraindications to metformin including severe allergic reactions and intolerance

16. Patients who are not eligible for this study, as Assessed by Investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xiangya Hospital of Central South University

OTHER

Sponsor Role: collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role: collaborator

Hunan Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

Lin Wu

Chief physician, director of department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lin Wu

Role: PRINCIPAL_INVESTIGATOR

Hunan Cancer Hospital

Locations

Hunan Cancer hospital

Changsha, Hunan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lin Wu, Prof.

Role: CONTACT

wulin-calf@vip.163.com

+86 13170419973

Xingxiang Pu, Prof.

Role: CONTACT

pxx_1354@163.com

+86 15874180022

Facility Contacts

Xing xiang Pu, Dr.

Role: primary

puxingxiang@hnca.org.cn

+86 0731-89762301

Lin Wu, Dr.

Role: backup

wulin-calf@vip.163.com

+86 0731-89762300

References

Aden D, Sureka N, Zaheer S, Chaurasia JK, Zaheer S. Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment. Immunology. 2025 Jan;174(1):30-72. doi: 10.1111/imm.13871. Epub 2024 Oct 27.

Reference Type: DERIVED

PMID: 39462179 (View on PubMed)

Other Identifiers

HNCH-SCLC-2019260

Identifier Type: -

Identifier Source: org_study_id